Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urologica e Nefrologica 2019 April;71(2) > Minerva Urologica e Nefrologica 2019 April;71(2):181-4



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Urologica e Nefrologica 2019 April;71(2):181-4

DOI: 10.23736/S0393-2249.18.03109-0


language: English

Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study

Antonio ALIBERTI 1, Maida BADA 2 , Sebastiano RAPISARDA 3, Clara NATOLI 4, Luigi SCHIPS 2, Luca CINDOLO 5

1 Department of Urology, Romagna Local Health Service, Forlì Hospital, Forlì, Italy; 2 Department of Urology, SS Annunziata Hospital, “G. D’Annunzio” University of Chieti, Chieti, Italy; 3 Department of Urology, “Gaspare Rodolico” Hospital, University of Catania, Catania, Italy; 4 Department of Medical, Oral and Biotechnological Sciences, Centro Scienze dell’Invecchiamento e Medicina Traslazionale (CeSI-MeT), “G. D’Annunzio” University of Chieti, Chieti, Italy; 5 Department of Urology, ASL Abruzzo 2, Chieti, Italy

BACKGROUND: Androgen-deprivation therapy is one of the options available for treating both advanced and metastatic prostate cancer (PCa). It is used as an adjuvant or neoadjuvant therapy, either alone or in combination with radiotherapy (RT) or surgery. The aim of this study was to appraise adherence to androgen-deprivation therapy (ADT).
METHODS: A total of 136 PCa patients on ADT (leuprorelin, triptorelin, and degarelix) were monitored between January 2008 and December 2015. Demographic, histopathological, and clinical data were collected.
RESULTS: Mean age was 76 years and PSA was 91.9 ng/mL. Forty-six patients (34%) had a Gleason Score >7. One hundred and eight patients were treated exclusively with ADT (53 [49%] leuprorelin, 45 [42%] triptorelin, and 10 [9%] degarelix). Mean follow-up was 3.5 years, with a mean overall prescription time of 3.4 years. Adherence to ADT was 95%. Sixty-three patients are currently on therapy, while 45 have discontinued treatment. Reasons for discontinuation were death (56%), physician’s choice (33%), and patient’s preferences (11%).
CONCLUSIONS: Adherence to ADT was optimal, probably owing to its balanced side effect and benefit profile. Patient’s death was the most frequent reason for discontinuation.

KEY WORDS: Prostatic neoplasms; Androgens; Treatment adherence and compliance

top of page